Work

Abstract CT215: Efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct215

Authors: David Paul Carbone, Saiama N. Waqar, Jamie E. Chaft, Mark G. Kris, Bruce E. Johnson, Jay M. Lee, Ignacio I. Wistuba, David Kwiatkowski, Paul Bunn, Katja Schulze, Ann Johnson, Evelise Brandao, Mark Awad, Karen L. Reckamp, Anne C. Chiang, Alan Nicholas, Valerie Rusch

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of California, Los Angeles, The University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, University of Colorado Cancer Center, Cedars-Sinai Medical Center, Yale Cancer Center, Yale University, Genentech

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365512001

Cites:

Cited by: 1

Related to: 10